Extended Endocrine Therapy and Survival for Breast Cancer Subtypes in Premenopausal Patients

Are there differences in the risks of invasive and distant recurrence across all surrogate breast cancer subtypes among patients with node-positive, hormone receptor–positive breast cancer who remain premenopausal after completing 5 years of adjuvant therapy with a luteinizing hormone–releasing hormone agonist and received or did not receive extended endocrine therapy (EET)?In this cohort study that included 487 patients, EET had a lower risk estimate than no EET for invasive breast cancer–free survival among patients with luminal A–like, luminal B–like, or -positive disease.A lower estimated risk with EET was observed across all surrogate breast cancer subtypes.

Corresponding Author: Giuseppe Curigliano, MD, PhD, Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Via Ripamonti 435, Milan 20141, Italy (giuseppe.curigliano@ieo.it).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.